A randomised trial of standard anthracycline-based chemotherapy with fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF) versus FEC followed by sequential docetaxel as adjuvant treatment for women with early breast cancer
Not Applicable
Completed
- Conditions
- Breast cancerCancerBreast
- Registration Number
- ISRCTN79718493
- Lead Sponsor
- Sponsor not defined - Record supplied by Institute of Cancer Research
- Brief Summary
2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19447249
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 3340
Inclusion Criteria
1. Patients with operable histologically confirmed completely resected invasive breast cancer for whom adjuvant chemotherapy is indicated
2. No clinical or radiological evidence of locoregional or metastatic disease based on standard staging procedures at local centres
3. World Health Organisation (WHO) performance status of zero or one
4. Chemotherapy to start within eight weeks from date of definitive surgery
5. Aged over 18 years (no upper age limit)
6. Hormone receptor status to be determined prior to randomisation
7. Adequate renal, hepatic and bone marrow function
8. Signed written informed consent
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration